转自：成都日报锦观 聚力产业链 区（市）县如何"拼" 全市"新春第一会"彰显了推动重点产业链"强链突破、聚链成群"的坚定决心，为各区（市）县以重点产 业链高质量发展支撑"十五五"开好局、起好步指明了方向。如何贯彻落实会议精神，推动重点产业链高 质量发展？来看各区（市）县怎么干—— 不少区（市）县表示，要巩固提升传统优势产业、加速突破新兴赛道，培植更具带动力的特色产业集 群。 2026年，新津区将拓展预制食品、功能食品、宠物食品等细分赛道，促进正大肉制品西南总部基地、新 希望健康食品产业园等重大项目加快建设，打造全省健康食品科技创新中心。 梯次培育 聚链强链 统筹推进传统产业改造升级、新兴产业培育壮大、未来产业布局建设，各区（市）县有何打算？ 成都高新区将加快推进集成电路重大项目建设，补齐产业链上下游存在的短板弱项；四川天府新区将锚 定战略性新兴产业和未来产业，加力加劲培育链主企业、夯实要素保障、做强项目支撑，以更大担当、 更实举措推动产业提质升级；成都东部新区将做强燃气轮机、氢能内燃机、无人机等装备制造产业的关 键环节，抢占可持续航空燃料产业新赛道。 温江区将围绕产业链补短板等方向开展项目谋划，全力推动西部放 ...

2月6日，新诺威盘中上涨2.05%，截至10:08，报35.38元/股，成交1.05亿元，换手率0.22%，总市值 496.94亿元。 截至1月30日，新诺威股东户数1.75万，较上期增加0.28%；人均流通股80349股，较上期减少0.27%。 2025年1月-9月，新诺威实现营业收入15.93亿元，同比增长7.71%；归母净利润-2404.89万元，同比减少 117.26%。 分红方面，新诺威A股上市后累计派现6.51亿元。近三年，累计派现5.00亿元。 机构持仓方面，截止2025年9月30日，新诺威十大流通股东中，香港中央结算有限公司位居第二大流通 股东，持股1778.22万股，相比上期减少321.69万股。中欧医疗健康混合A（003095）位居第三大流通股 东，持股1632.25万股，相比上期减少386.14万股。工银前沿医疗股票A（001717）位居第四大流通股 东，持股1400.01万股，相比上期增加200.01万股。汇添富创新医药混合A（006113）位居第五大流通股 东，持股1227.70万股，相比上期增加248.44万股。易方达创业板ETF（159915）位居第九大流通股东， 持股786.8 ...

今年是"十五五"开局之年。政府工作报告在部署今年工作时提出，"大力发展县域经济、民营经 济、开放型经济、数字经济""推动经济实现质的有效提升和量的合理增长"。 出席今年省两会的代表和委员在审议讨论政府工作报告时，结合各自领域和工作实际，就狠抓项目 建设、加快产业升级、激发民营经济活力、优化营商环境、扩大对外开放、壮大县域经济等话题建言献 策。 代表、委员表示，要坚持项目为王、产业为基，以更大力度深化改革开放创新，持续优化营商环 境，充分激发各类经营主体活力，为谱写陕西新篇、争做西部示范注入强劲动能。 抓项目强产业 "133万亩茶园，1965家经营主体，稳居全省茶产业三项指标第一，汉中已成为西北地区最大茶叶生 产加工基地和集散中心。"省人大代表、陕西省茶文化研究会会长张为国细数汉中茶产业发展成果。 2025年，汉中茶产业以科技创新为加速器，龙头企业与高校产学研合作打造茶多酚生产线、开发功 能食品，物联网、大数据技术让茶园实现智能化管理，规模化、标准化茶园占比超65%，茶产业走出现 代化升级之路，成为乡村特色产业发展的典范，为城乡融合发展筑牢产业支撑。 优化营商环境 充分激发经营主体活力 民营企业是现代化产业体系 ...

Group 1 - The Shandong Provincial Government is focusing on the development of key industries, including new generation information technology and artificial intelligence, as well as emerging sectors like life health and green energy, as part of its "10+1" industrial development strategy [2] - Qingdao University is aligning its academic programs with the regional industrial layout by establishing interdisciplinary doctoral programs in areas such as low-altitude technology and artificial intelligence [2][3] - The university has formed seven academic clusters from 39 disciplines, emphasizing peak disciplines in systems, textiles, and medicine, while also developing advantageous clusters in new energy and cultural creativity [3] Group 2 - Qingdao University has established its own medical technology company to leverage its clinical advantages, focusing on smart medical devices and innovative healthcare solutions [4] - The university is actively promoting the construction of research centers in extreme environment medicine and artificial intelligence, with several projects already approved or in progress [3] - The integration of AI into various research initiatives is a priority for Qingdao University, aiming to enhance its contributions to the local economy and healthcare innovation [2][4]

Group 1 - The Shandong Provincial People's Congress emphasized the importance of a first-class university named after a city as a hallmark of a modern international metropolis, with a focus on high-quality development of local universities and application-oriented institutions [1] - Qingdao University aims to leverage its strengths in medicine, healthcare, and engineering to contribute to the development of the Qingdao Science and Technology Innovation Corridor and the "China Health Bay" initiative, presenting both challenges and opportunities for the institution [1] Group 2 - Qingdao City has outlined a "10+1" industrial development strategy focusing on emerging industries such as new generation information technology, artificial intelligence, and health, while also enhancing existing industries like smart home appliances and high-end chemicals [2] - Qingdao University has established eight interdisciplinary doctoral programs in areas such as low-altitude technology and artificial intelligence, fostering a collaborative ecosystem through the integration of education and industry [2] Group 3 - Qingdao University has organized 39 first-level disciplines into seven discipline clusters, with a focus on developing peak discipline clusters in "system+", "textile+", and "medicine+" [3] - The university is actively promoting projects related to extreme environment special medicine and artificial intelligence, with plans for future energy and intelligent connected vehicle centers [3] Group 4 - Qingdao University has established its own wholly-owned medical technology company to incubate innovations in smart diagnostics, medical devices, and pharmaceuticals, aiming to create a strong brand in medical technology [4]

Core Viewpoint - New Nuo Wei's stock price has shown fluctuations, with a year-to-date increase of 7.46% but a recent decline of 5.42% over the past five trading days, indicating volatility in investor sentiment and market performance [2]. Company Overview - New Nuo Wei, established on April 5, 2006, and listed on March 22, 2019, is based in Shijiazhuang, Hebei Province. The company specializes in the research, production, and sales of functional foods, with its main revenue sources being functional foods and raw materials (88.93%), biopharmaceuticals (8.91%), and others (2.16%) [2]. - The company operates within the pharmaceutical and biological sector, specifically in chemical pharmaceuticals and raw materials, and is associated with various concept sectors including large-cap stocks, margin financing, fund holdings, vitamins, and innovative drugs [2]. Financial Performance - For the period from January to September 2025, New Nuo Wei reported a revenue of 1.593 billion yuan, reflecting a year-on-year growth of 7.71%. However, the net profit attributable to shareholders was a loss of 24.0489 million yuan, a significant decrease of 117.26% compared to the previous year [2]. - Since its A-share listing, New Nuo Wei has distributed a total of 651 million yuan in dividends, with 500 million yuan distributed over the last three years [3]. Shareholder Structure - As of September 30, 2025, New Nuo Wei had 20,700 shareholders, a decrease of 15.05% from the previous period. The average number of circulating shares per shareholder increased by 17.72% to 67,930 shares [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 17.7822 million shares (a decrease of 3.2169 million shares), and several mutual funds with varying changes in their holdings [3].

Core Insights - The "Biological Resource Development and Utilization Pilot Service Platform" has been approved as a provincial pilot platform, indicating recognition of its technical service capabilities and role in the biological resource development sector [1] Group 1: Platform Recognition and Purpose - The platform serves as a critical link between laboratory research and industrial production, facilitating the scaling up of successful lab results under simulated industrial conditions [1] - The recognition by the Fujian Provincial Department of Industry and Information Technology includes 14 pilot platforms across nine key industrial sectors, aimed at accelerating the engineering breakthroughs and market transformation of technological innovations [1] Group 2: Platform Development and Services - The Ocean Research Institute has been exploring the construction and operation of the pilot platform since 2010, supported by national and local projects, resulting in a comprehensive biotechnology pilot service platform equipped with essential testing equipment [1] - The platform is applicable to various product categories, including biomedicine, functional foods, biological products, and cosmetics [1] - A multi-tiered technical service and development model has been established, targeting enterprises, research institutions, industrial parks, local governments, and industry associations, providing services such as pilot testing, new product development, quality enhancement, and personnel training [2] - The establishment of a third-party pilot model for technology transfer has significantly improved the efficiency and success rate of converting research results into practical applications [2]

新诺威所属申万行业为：医药生物-化学制药-原料药。所属概念板块包括：融资融券、大盘、基金重 仓、维生素、创新药等。 截至12月10日，新诺威股东户数2.43万，较上期增加4.36%；人均流通股57704股，较上期减少4.17%。 2025年1月-9月，新诺威实现营业收入15.93亿元，同比增长7.71%；归母净利润-2404.89万元，同比减少 117.26%。 分红方面，新诺威A股上市后累计派现6.51亿元。近三年，累计派现5.00亿元。 机构持仓方面，截止2025年9月30日，新诺威十大流通股东中，香港中央结算有限公司位居第二大流通 股东，持股1778.22万股，相比上期减少321.69万股。中欧医疗健康混合A（003095）位居第三大流通股 东，持股1632.25万股，相比上期减少386.14万股。工银前沿医疗股票A（001717）位居第四大流通股 东，持股1400.01万股，相比上期增加200.01万股。汇添富创新医药混合A（006113）位居第五大流通股 东，持股1227.70万股，相比上期增加248.44万股。易方达创业板ETF（159915）位居第九大流通股东， 持股786.80万股，相比上期减 ...

Core Viewpoint - Starting in 2024, the performance of CSPC Pharmaceutical Group has shown a "double decline" in profits and revenues [1][23]. Group 1: Company Developments - CSPC Pharmaceutical Group has been active recently, establishing a joint venture named "CSPC Runshi Biotechnology" with a total investment of 450 million yuan, focusing on the development and commercialization of GLP-1 target-related drugs for diabetes and weight loss [2][17]. - A significant management reshuffle occurred on December 19, with Zhang Cuilong stepping down as CEO and being replaced by Cai Lei, who is the son of the company's chairman and major shareholder, Cai Dongchen [3][9][28]. - Cai Lei's appointment is seen as adding a family business dynamic to the leadership, as he is part of the next generation of the Cai family involved in the company [3][10]. Group 2: Financial Performance - CSPC's revenue for 2024 is reported at 29.009 billion yuan, a decrease of 9.56% year-on-year, while the net profit attributable to shareholders fell by 25.9% to 4.328 billion yuan [13][33]. - The company has continued to experience revenue and profit declines into the first three quarters of 2025, with revenues of 19.891 billion yuan, down 12.32% year-on-year, and a net profit of 3.511 billion yuan, down 7.06% [13][33]. Group 3: Strategic Shifts - The decline in performance is attributed to the impact of national drug procurement policies on the pricing of core products [15][35]. - CSPC is accelerating its transition towards innovative drugs, with nearly 90 products in various stages of clinical trials and a focus on external partnerships to enhance market access and cash flow [15][35]. - The company is also pushing into the GLP-1 market, with at least five related products in the application or licensing stages, indicating a competitive strategy in a growing therapeutic area [17][37]. Group 4: Leadership and Governance - The new leadership structure, characterized by a "brotherly division of labor" model, aims to leverage individual strengths, mitigate operational risks, and ensure a balanced governance structure [5][25]. - Cai Lei's previous experience in the U.S. R&D division is expected to enhance CSPC's international strategy and innovation capabilities [17][37]. - The company has faced scrutiny due to insider trading issues involving former executives, which has influenced recent management changes [10][31].

Core Viewpoint - The recent management reshuffle at CSPC Pharmaceutical Group (01093.HK) is seen as a strategic move to address ongoing industry challenges and accelerate the company's transformation amid declining performance [1][3]. Group 1: Management Changes - Zhang Cuilong has stepped down as Vice Chairman, CEO, and Authorized Representative due to job relocation but will remain as an Executive Director [1]. - Cai Lei has been appointed as Vice Chairman, Executive Director, CEO, and Authorized Representative [1]. - Wei Qingjie has been appointed as Vice Chairman, Executive Director, and Chief Operating Officer [1]. Group 2: Financial Performance - CSPC's revenue for the first three quarters of 2025 was CNY 19.891 billion, a year-on-year decrease of 12.32%, while the net profit attributable to shareholders decreased by 7.06% to CNY 3.511 billion [3][4]. - The company has faced continuous pressure on its performance due to factors such as centralized procurement, with a significant average price reduction of 65.34% across 18 products [7]. - The revenue for 2024 was CNY 29.009 billion, down 9.56%, and the net profit attributable to shareholders dropped by 25.90% to CNY 4.328 billion [4][7]. Group 3: R&D Investments - CSPC has increased its R&D investment from CNY 3.987 billion in 2022 to CNY 5.191 billion in 2024, with a cumulative investment exceeding CNY 14 billion over three years, reflecting an annual growth rate of over 14% [6]. - The company has over 200 innovative drug projects in development, focusing on six major therapeutic areas, with expectations to submit over 50 new drugs or new indications for approval by the end of 2028 [6]. Group 4: Strategic Initiatives - Cai Lei's appointment aligns with CSPC's internationalization strategy, as he has been involved in overseas R&D and sales, with the company having over USD 16.6 billion in overseas licensing agreements [8]. - CSPC's subsidiary, CSPC Innovation, has submitted a prospectus for an IPO, which may support the company's global expansion efforts [9]. Group 5: Market Outlook - Morgan Stanley forecasts a 5% growth in sales and a 7% increase in recurring net profit for 2026, with acceleration expected in 2027 [10]. - The company faces challenges related to internal governance, particularly following the insider trading penalty imposed on a former executive [10].